Ros Deegan

Flagship announces a collaboration with Cambridge University Health Partners and Milner Therapeutics Institute to accelerate biotech research and innovation. This alliance will engage top research institutes in Cambridge, UK, fostering a dynamic ecosystem for scientific breakthroughs and talent development: https://bit.ly/4gcCJoK

239

3 Comments

One Biosciences, a precision oncology startup specialising in clinical-grade single-cell tumour profiling, has raised €15 million in Series A funding, bringing its total funding to €20 million. The funding round was co-led by Redmile Group and Blast, with participation from Galion.exe, Invus, Adamed Technology, Sofinnova Partners, Polytechnique Ventures, and Kima Ventures. Hedi Ben Brahim | Magali RICHARD | Céline Vallot | Frédéric Danzi | Isabelle Pelletier-Bressac | Isabelle Pelletier-Bressac | Scott Braunstein | David Schilansky 🔗 Read full article link in comment #OneBiosciences #PrecisionOncology #SingleCellTech #funding #SeriesA #Biotech #eustartups #news

137

3 Comments

Not sure what the answer is but something needs to change in the U.K. if the “life sciences” sector is going to become a growth driver for the U.K. on its current trajectory it will continue to decline from an R&D investment and manufacturing perspective. ‘Backward’ UK market puts investment in life sciences at risk https://lnkd.in/eAzfiW73

164

7 Comments

Combination therapies in oncology hold huge potential for improving patient outcomes, yet reimbursement of combination therapy across the UK and EU remains varied and limited in many markets. In this article in Drug Target Review, Anastasia Stamoulou, Jennifer Gaultney and Saskia van Dijk discuss the barriers to positive HTA outcomes and the need for a multistakeholder approach to the solution. Read their insights in full. https://lnkd.in/eHtJFDfU

64

Explore the final article in Uniphar's three-part series with FirstWord Pharma - focused on preparing cell and gene therapies (CGTs) for successful launch and long-term viability. This latest piece delves into the earliest stages: preclinical and phase 1. Tom Smith, Maurice Leonard and Wayne McGarry highlight the value of embedding commercial thinking from the outset - across regulatory, clinical, manufacturing, and access planning - to position CGT assets for broad, timely, and economically sustainable patient access. Read the full article: https://lnkd.in/eJZSQpze #cellandgene #Uniphar #advancedtherapies

51

Fantastic to see Trogenix close one of Europe’s largest early-stage biotech rounds this year—a £70M Series A to advance potentially curative therapies for aggressive cancers. This milestone highlights the transformative potential of their Odysseus® platform and Scotland’s growing leadership in cell and gene therapy.   Scottish Enterprise supports Trogenix through strategic account management, and long-term investment in the Edinburgh BioQuarter —home to the CGT Catapult and the world’s largest academic grouping in cell and gene therapy and tissue engineering. Following initial support through our High Growth Spin Out Programme, Trogenix has benefited from assistance with investment readiness, intellectual property and ongoing guidance and scaling support from our High Growth Companies Team.    From exciting spinouts like RoslinCT, Resolution Therapeutics and Trogenix to cutting-edge facilities and funding, Scotland provides a world-class environment for companies tackling global health challenges.   We’ll continue to back ambition in this vital sector.   #WeBackAmbition #LifeSciences #CGTCatapult #Trogenix

107

'We need to move with the times' - Matthew Durdy, Chief Executive, Cell and Gene Therapy Catapult.   In this Pink Sheet interview, Matthew Durdy, CGT Catapult, discusses how recent changes in UK drug regulations could impact the #cell and #gene therapy industry, and how the Medicines and Healthcare products Regulatory Agency (MHRA)'s new reforms in decentralised manufacturing are a positive signal for the UK's #CellTherapy ecosystem.   Read the interview: https://lnkd.in/eK4AR8BG   #ATMPs #AdvancedTherapies Citeline

47

3 Comments

As Biocon Biologics picks up the latest approvals in Europe for its ustekinumab biosimilar, Blake Leitch, the firm’s head of Europe, talks to Generics Bulletin about what lies ahead for Biocon and for biosimilars more widely in the region – including tackling the “biosimilar void”. https://lnkd.in/epnMsSg5

55

2 Comments

We recently celebrated the opening of the Functional Genomics Screening Laboratory (FGSL) in Cambridge, a unique cross-sector partnership co-funded by Milner Therapeutics Institute , Medical Research Council and AstraZeneca, that is central to the UK Human Functional Genomics Initiative . The newly launched FGSL supports world-class research in the rapidly advancing field of functional genomics, which explores links between genes and diseases to uncover new therapeutic targets and accelerate drug discovery. It will be the first centre in the UK to offer advanced CRISPR screening on this scale for chronic diseases through collaborations with researchers across the UK. Genomics is an integral part of our R&D strategy at AstraZeneca and we believe scientific innovation and collaboration go hand-in-hand. We look forward to the insights this pioneering partnership will unlock as we share resources and expertise to push the boundaries of what science can do. 📣 Proposals to collaborate with the FGSL can be submitted here: https://learn.az/6045FK68S #WhatScienceCanDo #FunctionalGenomics Photo credits: Eames Photography and Lloyd Mann.

54

1 Comment

Our CEO, Peter Anastasiou, spoke with Matthew Pillar on the #BusinessofBiotech podcast to discuss the challenges and opportunities in the gene therapy field and how, at Capsida, we are overcoming those challenges to unlock the full potential of gene therapy for all. Our progress includes entering the clinic this year with our lead programs for STXBP1 developmental and epileptic encephalopathy and Parkinson's caused by GBA mutations, marking a major step toward bringing innovative products to patients. We are also proud to continue to advance and support the programs of our partners AbbVie, Lilly, Kate Tx/Novartis, and CRISPR Tx. Peter emphasized our work is not just for science's sake, but in the service of patients. Tune in to the full discussion here: https://lnkd.in/gCaRx9DW Swipe below for some highlights from the conversation #Biopharma #Biotech #GeneTherapy #Biotechnology

44

3 Comments